Celltrion’s biosimilar 'Remsima' was selected as a treatment ahead of the original drug in Norway Dr

Published: 2014-01-29 07:00:00

Updated: 2014-01-29 07:00:00

Celltrion’s biosimilar 'Remsima' was selected as a treatment ahead of the original drug in Norway Drug national bid

(Yakup Shinmoon)

On Jan 24, Celltrion announced that the world's first antibody biosimilar 'Remsima' was selected as a treatment for rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis, ahead of the original drug in Norway Drug national bid ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.